Amylin, with and without GLP1: Eloralinitide

We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.

Amylin, with and without GLP1: Eloralinitide

As part of Eli Lilly's upcoming flurry of updates, one of their projects that is under way deserves a bigger spot light: Eloralinitide.

Eloralinitide isn't a GLP1 Receptor Agonist in it's own right – it's actually a drug meant to be taken alongside a GLP1 regimen, enhancing it's effects.

🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

By the '-tide' name, we know that it's a peptide (similar to Retatrutide though Retatrutide is itself a GLP1 receptor agonist peptide).

What is Eloralinitide?

Eloralinitide is an analog to the naturally produced Amylin hormone:

Amylin - Wikipedia

To briefly summarize the key properties of Amylin:

  • It's secreted at the same time as insulin
  • Impacts the pancreas
  • It helps control blood sugar
  • It slows gastric emptying
  • Increases fullness after meals

Amylin is actually another powerful force in the reduction of appetite after eating in the human body.

Want to read more on Eloralinitide and the related research?